426 related articles for article (PubMed ID: 30904097)
1. Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies.
McEneaney LJ; Tee AR
Adv Genet; 2019; 103():91-118. PubMed ID: 30904097
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
3. [Tuberous Sclerosis Complex].
Kaneda M
Brain Nerve; 2019 Apr; 71(4):374-379. PubMed ID: 30988224
[TBL] [Abstract][Full Text] [Related]
4. Renal disease in tuberous sclerosis complex: pathogenesis and therapy.
Lam HC; Siroky BJ; Henske EP
Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410
[TBL] [Abstract][Full Text] [Related]
5. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
Pal R; Xiong Y; Sardiello M
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
[TBL] [Abstract][Full Text] [Related]
6. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
7. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
[TBL] [Abstract][Full Text] [Related]
8. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
9. An Insight of Scientific Developments in TSC for Better Therapeutic Strategy.
Natarajan N; Thiruvenkatam V
Curr Top Med Chem; 2020; 20(23):2080-2093. PubMed ID: 32842942
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of TSC1 and TSC2 genes in Tuberous Sclerosis Complex patients from Greece.
Avgeris S; Fostira F; Vagena A; Ninios Y; Delimitsou A; Vodicka R; Vrtel R; Youroukos S; Stravopodis DJ; Vlassi M; Astrinidis A; Yannoukakos D; Voutsinas GE
Sci Rep; 2017 Dec; 7(1):16697. PubMed ID: 29196670
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex.
Lu Y; Zhang EY; Liu J; Yu JJ
Orphanet J Rare Dis; 2020 Aug; 15(1):209. PubMed ID: 32807195
[TBL] [Abstract][Full Text] [Related]
12. Genetics, genomics, and genotype-phenotype correlations of TSC: Insights for clinical practice.
Peron A; Au KS; Northrup H
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):281-290. PubMed ID: 30255984
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of TSC1 and TSC2 in Danish patients with tuberous sclerosis complex.
Rosengren T; Nanhoe S; de Almeida LGD; Schönewolf-Greulich B; Larsen LJ; Hey CAB; Dunø M; Ek J; Risom L; Nellist M; Møller LB
Sci Rep; 2020 Jun; 10(1):9909. PubMed ID: 32555378
[TBL] [Abstract][Full Text] [Related]
14. Revisiting Brain Tuberous Sclerosis Complex in Rat and Human: Shared Molecular and Cellular Pathology Leads to Distinct Neurophysiological and Behavioral Phenotypes.
Kútna V; O'Leary VB; Newman E; Hoschl C; Ovsepian SV
Neurotherapeutics; 2021 Apr; 18(2):845-858. PubMed ID: 33398801
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
16. Tuberous Sclerosis Complex in Chinese patients: Phenotypic analysis and mutational screening of TSC1/TSC2 genes.
Lin S; Zeng JB; Zhao GX; Yang ZZ; Huang HP; Lin MT; Wu ZY; Wang N; Chen WJ; Fang L
Seizure; 2019 Oct; 71():322-327. PubMed ID: 31525612
[TBL] [Abstract][Full Text] [Related]
17. A Bama miniature pig model of monoallelic TSC1 mutation for human tuberous sclerosis complex.
Li X; Hu T; Liu J; Fang B; Geng X; Xiong Q; Zhang L; Jin Y; Liu X; Li L; Wang Y; Li R; Bai X; Yang H; Dai Y
J Genet Genomics; 2020 Dec; 47(12):735-742. PubMed ID: 33612456
[TBL] [Abstract][Full Text] [Related]
18. The genomic landscape of tuberous sclerosis complex.
Martin KR; Zhou W; Bowman MJ; Shih J; Au KS; Dittenhafer-Reed KE; Sisson KA; Koeman J; Weisenberger DJ; Cottingham SL; DeRoos ST; Devinsky O; Winn ME; Cherniack AD; Shen H; Northrup H; Krueger DA; MacKeigan JP
Nat Commun; 2017 Jun; 8():15816. PubMed ID: 28643795
[TBL] [Abstract][Full Text] [Related]
19. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
20. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.
Inoki K; Guan KL
Hum Mol Genet; 2009 Apr; 18(R1):R94-100. PubMed ID: 19297407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
